New drug combo vs standard care for limited-stage small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of drugs (atigotatug and nivolumab) against the standard drug durvalumab for people with limited-stage small cell lung cancer who have completed chemotherapy and radiation without the cancer getting worse. The goal is to see if the new combination works better at keeping the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have limited-stage small cell lung cancer (cancer that has not spread far in the chest).
- You must have finished chemotherapy and radiation therapy together, and your cancer must not have grown during that treatment.
- You must be in good physical condition (able to do daily activities without help).
- You must not have serious heart problems, active autoimmune diseases, or other cancers that are still growing.
- You must not have had previous treatment with immunotherapy drugs like PD-1 or PD-L1 inhibitors.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a new drug called tarlatamab to a standard immunotherapy (durvalumab) works better than durvalumab alone for small cell lung cancer that hasn't spread widely. You would be eligible if you've already completed chemotherapy and radiation therapy and your cancer hasn't gotten worse.
This trial tests long-term use of durvalumab (an immunotherapy drug) after standard chemotherapy and radiation for limited-stage small cell lung cancer. It may keep the cancer from coming back.
This trial tests a new combination of drugs (BMS-986489 with chemotherapy) against the current standard treatment (atezolizumab with chemotherapy) for people who have just been diagnosed with extensive-stage small cell lung cancer. It aims to see which approach works better and is safer.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This trial tests adding the immunotherapy drug durvalumab to standard chemotherapy and radiation for limited-stage small cell lung cancer. The goal is to see if this combination helps control the cancer better than standard treatment alone.
This trial tests adding a new drug, iadademstat, to standard immunotherapy drugs (atezolizumab or durvalumab) for people with small cell lung cancer that responded to initial treatment. The goal is to see if this combination works better at preventing cancer from returning.
Hear when a new Limited Stage Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.